Cinclus Pharma Holding AB (FRA:J8P) Short Percentage of Float


FRA:J8P Cinclus Pharma Holding AB FRA:J8P
4 GF Score
Price €0.99
! 3 Warning Signs
View Full Analysis

What is Cinclus Pharma Holding AB Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:J8P vs ZTS, UTHR: Short Percentage of Float Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cinclus Pharma Holding AB's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cinclus Pharma Holding AB Short Percentage of Float vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cinclus Pharma Holding AB's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Cinclus Pharma Holding AB's Short Percentage of Float falls into.


FRA:J8P
4GF Score
Cinclus Pharma Holding AB FRA:J8P
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cinclus Pharma Holding AB Business Description

Other Exchanges CINPHA:Sweden
Address Kungsbron 1, Stockholm, SWE, SE-111 22
Cinclus Pharma Holding AB is a Swedish clinical-stage pharmaceutical company focused on developing small-molecule treatments for gastric acid-related diseases. Its candidate, linaprazan glurate, is being developed for the treatment of severe gastroesophageal reflux disease, including erosive forms. The company is also developing a dual therapy treatment with an antibiotic targeting Helicobacter pylori, a bacterium found in the gastric and duodenal mucosa. Its primary target population consists of patients with severe erosive gastroesophageal reflux disease, where current treatment options are limited. It operates in Switzerland, Sweden, and the Czech Republic, with the majority of revenue from the Czech Republic.
4GF Score

Get the complete analysis for FRA:J8P

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.99
Price